GUIDELINES FOR THE DOSAGE OF NEUROLEPTICS .2. CHANGING FROM DAILY ORAL TO LONG-ACTING INJECTABLE NEUROLEPTICS

被引：22
作者：
SCHULZ, P
REY, MJ
DICK, P
TISSOT, R
机构：
来源：
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 1989年 / 4卷 / 02期
关键词：
D O I：
10.1097/00004850-198904000-00002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：105 / 114
页数：10
相关论文
共 23 条
[1]  
AAESJORGENSEN T, 1983, PSYCHOPHARMACOLOGY, V81, P68
[2]   THEORETICAL AND PRACTICAL IMPORTANCE OF PLASMA-LEVELS OF HALOPERIDOL - CORRELATIONS WITH CLINICAL AND COMPUTERIZED EEG DATA [J].
DEBUCK, RP ;
ZELASCHI, N ;
GILLES, C ;
DURDU, J ;
BRAUMAN, H .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1981, 5 (5-6) :499-502
[3]  
DESCHEPPER PJ, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1056
[4]   FLUPHENAZINE PHARMACOKINETICS AND THERAPEUTIC RESPONSE [J].
DYSKEN, MW ;
JAVAID, JI ;
CHANG, SS ;
SCHAFFER, C ;
SHAHID, A ;
DAVIS, JM .
PSYCHOPHARMACOLOGY, 1981, 73 (03) :205-210
[5]  
ERESHEFSKY L, 1984, CLIN IMPLICATIONS FL, P1
[6]  
FORSMAN A, 1976, CURR THER RES CLIN E, V20, P319
[7]  
FORSMAN A, 1979, BIOL PSYCHIATRY TODA, P949
[8]  
HANSEN CE, 1976, BRIT J CLIN PHARMACO, V3, P915
[9]   HALOPERIDOL KINETICS AFTER ORAL AND INTRAVENOUS DOSES [J].
HOLLEY, FO ;
MAGLIOZZI, JR ;
STANSKI, DR ;
LOMBROZO, L ;
HOLLISTER, LE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (04) :477-484
[10]  
HOLLISTER LM, 1978, CLIN PHARM PSYCHOTHE, P165
123